UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the Month of March 2026
Commission File Number 001-35948
Kamada Ltd.
(Translation of registrant’s name into English)
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
This Form 6-K is being incorporated by reference
into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720,
333-207933, 333-215983,
333-222891, 333-233267
and 333-265866.
The following exhibit is attached:
| 99.1 |
|
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 26, 2026 |
KAMADA LTD. |
| |
|
| |
By: |
/s/ Nir Livneh |
| |
|
Nir Livneh |
| |
|
Vice President General Counsel and
Corporate Secretary |
EXHIBIT INDEX
| EXHIBIT NO. |
|
DESCRIPTION |
| 99.1 |
|
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas |
3
Exhibit 99.1
Kamada Announces FDA Approval of its Plasma
Collection Center in San Antonio, Texas
| ● | San
Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma |
| ● | State
of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution
of $8 Million to $10 Million at its Full Capacity |
| ● | The
Center is Structured to Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D; Anticipated to be One of the
Largest Centers for Specialty Plasma Collection in the U.S. |
REHOVOT, Israel, and HOBOKEN, NJ – March
26, 2026 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated
for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration
(FDA) has approved Kamada Plasma’s collection center in San Antonio, TX. The approval was obtained following an on-site inspection
made by the FDA during February 2026.
The center is now cleared to commence commercial
sales of normal source plasma. The 11,100 square foot San Antonio facility supports up to 50 donor beds, with a planned capacity of approximately
50,000 liters per year at its full capacity, and is anticipated to be one of the largest collection centers for specialty plasma in the
U.S.
“We are extremely pleased to announce the
FDA approval of our state-of-the-art plasma collection center in San Antonio, and for the work of our dedicated team of plasma collection
experts who achieved the approval of this facility,” said Amir London, Chief Executive Officer of Kamada. “Our three Texas-based
sites, in Houston, San Antonio and Beaumont, provide us with significant capacity of specialty and normal source plasma collection.”
Following FDA’s approval of the San Antonio
location, Kamada intends to seek a subsequent inspection and approval by the European Medicines Agency (EMA) of this site. The San Antonio
center is expected to generate annual revenues of $8 million to $10 million in sales of normal source plasma at its full capacity.
About Kamada
Kamada Ltd. (the “Company”) is a global
biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty
plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling
shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving
profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment
in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived
products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two types
of equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA
region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping
up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers,
and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection
centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions,
business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products
portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company
is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product
candidates, targeting areas of significant unmet medical need.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements
within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements
regarding 1) plasma collection center in San Antonio, TX has annual collection capacity of approximately 50,000 Liters of Plasma at its
full capacity, 2) the San Antonio center expected to generate estimated annual revenue of $8 Million to $10 Million in sales of normal
source plasma, at its full capacity, 3) the San Antonio center is anticipated to be one of the largest collection centers for specialty
plasma in the U.S., 4) expectations that the Company’s three Texas-based sites, in Houston, San Antonio and Beaumont will provide
significant capacity of specialty and normal source plasma collection, and 5) the Company’s intention to seek a subsequent inspection
and approval by the European Medicines Agency (EMA) for its San Antonio center. Forward-looking statements are based on Kamada’s
current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and
assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements
as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East with bombing of Iran
by the U.S. and Israel, and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts
on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, effect of potential
imposed tariff on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit
levels in light of such potential tariff, the effect on establishment and timing of business initiatives, Kamada’s ability to leverage
new business opportunities and integrate it with its existing product portfolio, regulatory delays, and other risks detailed in Kamada’s
filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report
on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s
website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes
no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required
by law.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
